Year: 2025

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally. The Medidata Experiences address the fragmented, standalone tools of the life sciences...

Verkkokauppa.com Oyj to commence share buyback program Verkkokauppa.com Oyj         STOCK EXCHANGE RELEASE        23 October 2025 at 7:45 a.m. EEST  The Board of Directors of Verkkokauppa.com has decided to initiate a share buyback program based on the authorization granted by the Annual General Meeting held on 8 April 2025. The company may repurchase up to 250,000 shares, representing approximately 0.6% of the total number of shares. The shares will be repurchased using the company’s unrestricted equity through public trading on Nasdaq Helsinki. The price for the shares will be based on the price prevailing on the market on the day of the repurchase in public trading. The maximum monetary amount to be used for the share repurchases is EUR 1,125,000. The program will commence on 28 October 2025 at the earliest and end on 28 January 2026...

VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it has granted 2,500,000 incentive stock options (“the Options”) to certain directors and consultants of the Company, exercisable at $0.55. 700,000 of the Options will expire in five years from the date of grant, 800,000 will expire in two years (subject to vesting provisions) from the date of grant and 1,000,000 will expire after 1 year from the date of grant. The Options, and any underlying common shares issued on exercise thereof, will have a hold period expiring 4 months and one day, in accordance with the policies of the CSE and applicable securities laws. The Options are subject to the terms and conditions of the Company’s stock option plan and the...

VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce the Company has closed the first tranche, representing the majority of its previously announced upsized non-brokered private placement (the “Upsized Offering”), raising gross proceeds of $25,134,145 through the issuance of 6,981,707 units (the “Units”) of the Company at a price of $3.60 per Unit. The Upsized Offering totals $26,775,648, with the final tranche of 455,973 Units for gross proceeds of $1,641,503 expected to close in the coming days. Each Unit issued pursuant to the Upsized Offering consists of one common share (a “Share”) in the capital of the Company and one common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder...

— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload — — Preclinical data shows robust antitumor activity with synergistic and bystander killing effects — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025, in Boston, USA. HMPL-A251 is a first-in-class PI3K/AKT/mTOR (“PAM”)-HER2 Antibody-Targeted Therapy...

Taipei, Taiwan., Oct. 22, 2025 (GLOBE NEWSWIRE) — Miluna Acquisition Corp (Nasdaq: MMTXU) (the “Company”), a Cayman Islands exempted company, announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “MMTXU” beginning on October 23, 2025. Each unit consists of one (1) ordinary share and one (1) redeemable warrant. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “MMTX” and “MMTXW”, respectively. D. Boral Capital LLC and ARC Group Securities LLC are acting as joint book-running managers in the offering. The underwriters have been granted a 45-day option to purchase up to an additional...

Hong Kong, Oct. 22, 2025 (GLOBE NEWSWIRE) — Raytech Holding Limited (NASDAQ: RAY) (the “Company”), a Hong Kong-headquartered company specializing in design, sourcing and wholesale of personal care electrical appliances for international brand owners, today announced, on October 14, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing or trading of the Company’s ordinary shares on Nasdaq. Nasdaq has provided the Company...